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KaOBJECTIVES The aim of this study was to identify clinical, procedural, and angiographic correlates of late/very late
drug-eluting stent (DES) thrombosis as well as to determine the clinical outcomes of these events.
BACKGROUND Late/very late DES thromboses are a poorly studied phenomenon, partly due to the relative
infrequency of these events, even in large cohort studies.
METHODS In the DESERT (International Drug-Eluting Stent Event Registry of Thrombosis), a retrospective, case-control
registry, 492 cases of late/very late deﬁnite DES thrombosis from 21 international sites were matched in a 1:1 fashion with
controls without stent thrombosis (ST). Controls were matched according to 2 criteria: same enrolling institution and date
of initial DES implantation. Baseline and procedural variables were collected, and clinical follow-up was obtained for
patients with ST as long as 1 year after the event. Ofﬂine quantitative coronary angiography was performed for a subset
of 378 case-control pairs.
RESULTS The majority of ST events occurred after 1 year (75%) and continued to occur for as long as 7.3 years. The
clinical presentation of late/very late ST events was mainly myocardial infarction (66.7% ST-segment elevation
myocardial infarction and 22.0% non–ST-segment elevation myocardial infarction); in-hospital mortality was 3.8%.
A minority of patients (30%) with ST were receiving dual-antiplatelet therapy at the time of the event. Independent
clinical correlates of late/very late ST were younger age, African-American race, current smoking, multivessel disease,
longer stented length, overlapping stents, and percutaneous coronary intervention of vein graft lesions. Independent
angiographic correlates for late/very late ST were lesions within the left anterior descending artery or a bypass graft,
thrombus, and a larger residual diameter stenosis after the initial DES implantation. Despite the large sample of ST cases,
all identiﬁed correlates of late/very late ST had weak associations with subsequent ST (all odds ratios <2.5).
CONCLUSIONS Despite a large sample of ST cases and use of limited matching to maximize the identiﬁcation of
predictive factors associated with late/very late ST, the variables associated with the development of late/very late ST
were only weakly predictive of subsequent events. Additionally, a relatively low observed mortality rate of ST in this
series may reﬂect a different pathophysiology of these late/very late events compared with acute/subacute ST.
(Drug Eluting Stent Registry of Thrombosis [DESERT]; NCT00812552) (J Am Coll Cardiol Intv 2014;7:1093–102)
© 2014 by the American College of Cardiology Foundation.m the *MedStar Washington Hospital Center, Washington, DC; yColumbia University Medical Center/New York–Presbyterian
spital/Cardiovascular Research Foundation, New York, New York; zSaint Luke’s Mid America Heart Institute, Kansas City,
nsas; xMaine Medical Center, Portland, Maine; kSwiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland;
{Wake For
**The Miri
investigato
Scientiﬁc, M
researchgr
forBiotron
Eli Lilly, Da
on the Spe
Abbott Vas
Manuscrip
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome
BMS = bare-metal stent(s)
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
IQR = interquartile range
LAD = left anterior descending
MI = myocardial infarction
PCI = percutaneous coronary
intervention
QCA = quantitative coronary
angiography
ST = stent thrombosis
STEMI = ST-elevation
myocardial infarction
SVG = saphenous vein graft
TIMI = Thrombolysis In
Myocardial Infarction
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1094S ince the introduction of bare metalstents (BMS), stent thrombosis (ST)has been a major concern due to signif-
icant morbidity and mortality (1–3). The wide-
spread adoption of dual-antiplatelet therapy
(DAPT) with aspirin and a P2Y12 receptor
antagonist (4) and improved percutaneous
coronary intervention (PCI) techniques (5)
have decreased the risk of thrombosis to an
acceptable level (<w1%), although the inci-
dence of ST remained higher when stents
were placed in more complex subjects and
lesions (2,6). Drug-eluting stents (DES) held
the promise of mitigating, if not abolishing,
restenosis and the need for repeat revascular-
ization procedures (7,8). Nonetheless, reports
of late ST events (beyond 30 days) with DES,
including data that demonstrated a constant
hazard of ST of 0.6%/year after DES implanta-
tion, led to continued concerns regarding the
safety of DES (9–15).SEE PAGE 1103Although the phenomenon of subacute ST has been
well described in the BMS era and still constitutes the
majority of ST events with DES, the predictors and
outcomes of late ST (30 days to 12 months) and very
late ST (beyond 12 months) with DES have been less
well understood, in part because of the low frequency
of these events. Previous reports have been limited to
small cohorts or case series (16–22). Furthermore, the
optimal duration of DAPT for patients undergoing DES
implantation and the relationship between the dura-
tion of DAPT and the occurrence of late/very late DES
thrombosis remains unclear. The aim of this prospec-
tive case-control study was to identify clinical, pro-
cedural, and angiographic correlates of late/very late
DES thrombosis, as well as to determine the clinical
outcomes of these events.
METHODS
STUDY POPULATION. The DESERT (International
Drug-Eluting Stent Event Registry of Thrombosis) wasest School of Medicine, Winston-Salem, North Carolina; #Lahey C
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t received March 17, 2014; accepted April 24, 2014.a retrospectively designed, multicenter, observa-
tional, case-control study with an original aim to
enroll as many as 500 patients with deﬁnite late/very
late DES thrombosis and 500 matched control pa-
tients (Figure 1). Patients with deﬁnite ST of a U.S.
Food and Drug Administration–approved DES after
April 2003 were included in the study. Included pa-
tients were 18 years of age and older and presented
with late/very late deﬁnite ST (per the Academic
Research Consortium deﬁnition) (23) conﬁrmed by
angiography or autopsy. Sites reported, to the best of
their knowledge, consecutive cases of late/very late
deﬁnite ST patients. A site was included if it 1) had an
internal systematic reporting mechanism to identify
stent thrombosis patients (i.e., databases) or 2) was
able to develop queries within its billing system to
identify readmission for ST presentations. Limited
matching was used: 492 cases of late/very late deﬁ-
nite DES thrombosis from 21 international sites were
matched in a 1:1 fashion with controls without ST.
Controls were matched according to 2 criteria: same
enrolling institution and date of initial DES implan-
tation. Control patients were eligible if they had no
known history of ST until the time of matching. In the
event that more than 1 control was eligible for a case,
the sites were instructed to randomly assign a
control. The rationale for limited matching was to
maximize identiﬁcation of covariates potentially
associated with late/very late ST (had more extensive
matching been used, this would have virtually elim-
inated the identiﬁcation of an association between
the matched covariates and the outcome of interest).
The baseline, clinical, procedural, and angiographic
characteristics at the time of initial DES implantation
and additional data regarding the ST presentation and
treatment procedure were collected using electronic
case report forms.
There was no treatment modality speciﬁed in this
protocol, and the registry did not require the treating
physicians to alter therapeutic strategies for either
initial stent implantation or ST episode. A subset of
case patients was followed after the thrombotic event
for as long as 12 months. The appropriate Healthlinic Medical Center, Burlington, Massachusetts; and
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TABLE 1 Baseline Demographic Factors at the Time of Drug-Eluting Stent Implantation
ST
(n ¼ 492)
Control
(n ¼ 492) p Value
Age, yrs 58.0  12.6 63.2  11.4 <0.001
Men, % 77.0 73.6 0.18
African American, % 10.2 6.3 0.02
Diabetes, % 25.8 29.3 0.22
Hypertension, % 66.3 73.3 0.02
Current smoker, % 45.9 27.3 <0.001
Previous cerebrovascular accident/transient
ischemic attack, %
7.6 9.0 0.43
History of peripheral vascular disease, % 9.6 9.8 0.91
History of chronic renal insufﬁciency, % 6.7 7.4 0.70
Dialysis, % 1.8 1.8 0.99
History of congestive heart failure, % 6.5 4.7 0.20
Current class (III/IV), % 1.2 1.8 0.44
Previous coronary artery bypass graft surgery, % 11.4 12.8 0.49
Previous percutaneous coronary intervention, % 34.4 26.1 0.005
Previous myocardial infarction, % 28.2 20.8 0.008
Previous ST (any), % 2.4 — —
Values are mean  SD.
ST ¼ stent thrombosis.
FIGURE 1 The DESERT Study Design
The DESERT study design was case-control with patients
matched to the same enrolling institution and within 3 days
of the thrombosed stent implantation. Two subgroups were
identiﬁed with a cohort of stent thrombosis (ST) patients
undergoing long-term follow-up after the ST presentation and
387 patient pairs undergoing ofﬂine quantitative coronary
angiography (QCA) analysis of the drug-eluting stent (DES)
implantation procedure and the ST angiograms of the case.
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1095Insurance Portability and Accountability Act waiver/
authorization or the appropriate informed consent
documentation requirement was obtained per insti-
tutional policy for the collection of data.
STUDY ENDPOINTS AND DEFINITIONS. Deﬁnite ST
had to meet the Academic Research Consortium
deﬁnition criteria (23): ST in the setting of an acute
coronary syndrome (ACS) conﬁrmed by angiography
or autopsy. Major adverse cardiac events were
deﬁned as the composite of all-cause death, Q-wave
myocardial infarction (MI), and target lesion revas-
cularization. Additionally, in-hospital stroke was
tracked and classiﬁed as either ischemic or hemor-
rhagic. Data on follow-up target vessel revasculari-
zation and recurrent thrombosis were also collected.
A random subgroup of 387 case-control pairs (79%)
underwent ofﬂine quantitative coronary angiography
(QCA) analysis. For these patients, QCA analysis was
performed of the original DES implantation pro-
cedures for both the ST patients (cases) and the con-
trol patients, as well as of the angiogram obtained at
the time of the ST presentation for the cases. All QCAs
were performed by an independent core laboratory
(Cardiovascular Research Foundation AngiographicCore Laboratory, New York, New York), and all
quantitative and qualitative deﬁnitions were estab-
lished before analyses commenced.
STATISTICAL ANALYSIS. Categorical variables are
reported as number and frequency, and continuous
variables are reported as mean  SD and median with
interquartile range where applicable. Because of
the matching process, comparison statistics were
done with the McNemar test for categorical data and
the paired t test or Wilcoxon signed rank test for
continuous data as appropriate. Potential predictors
of late/very late ST were identiﬁed independently
based on clinical and QCA (if available) data. Multi-
variable conditional logistic regression was used to
identify covariates independently associated with
late/very late ST. Candidate covariates either associ-
ated with ST in previous reports or associated with ST
in this study were considered for these analyses, such
as clinical risk factors, lesion characteristics, and
previous stent details.
RESULTS
CHARACTERISTICS AT THE TIME OF INDEX DES
IMPLANTATION. In the DESERT, a total of 984 pa-
tients (492 paired cases and controls) were enrolled
from 21 sites in the United States, Canada, Italy, and
Switzerland. Patients’ baseline demographic charac-
teristics and clinical presentation are displayed in
Tables 1 and 2. By design, there was minimal matching
of baseline characteristics (to identify correlates of
TABLE 2 Presentation at the Time of Drug-Eluting Stent Implantation
ST
(n ¼ 492)
Control
(n ¼ 492) p Value
ST-segment elevation myocardial infarction, % 20.2 13.6 0.004
Acute coronary syndrome/non–ST-segment
elevation myocardial infarction, %
25.5 21.1 0.11
Unstable angina, % 30.5 31.9 0.62
Stable angina, % 14.7 18.5 0.08
Positive functional test, % 15.7 19.3 0.13
Cardiogenic shock, % 0 1.0 —
Staged percutaneous coronary intervention, % 1.4 0.6 0.16
Other clinical presentation, % 4.9 7.5 0.07
Single-vessel disease, % 39.5 50.6 <0.001
2-vessel disease, % 35.0 28.5
3-vessel disease, % 25.5 20.9
Body mass index, kg/m2, % 28.8  5.9 29.8  6.8 0.02
Left ventricular ejection fraction, % 51  12 54  11 <0.001
Values are mean  SD.
ST ¼ stent thrombosis.
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1096ST using a case-control design); as such, there
were several differences between case and control
patients. At the time of initial DES implantation, pa-
tients with subsequent ST were younger, more often
smokers, and more frequently African American and
more frequently had a history of hypertension, MI,
and PCI. At the time of initial DES implantation, case
patients more frequently presented with ST-segment
elevation myocardial infarction (STEMI) and multi-
vessel disease and additionally had lower left ventric-
ular ejection fractions. The DES type distribution was
similar between groups, with one-half of the lesions
receiving sirolimus-eluting (50.2%), paclitaxel-eluting
(40.3%), everolimus-eluting (7%), and zotarolimus-
eluting (1.8%) stents.
Lesion characteristics at the time of DES implanta-
tion are displayed in Table 3. Overall, there were more
saphenous vein graft (SVG) lesions, left anterior
descending (LAD) locations, complex B2/C lesions, and
in-stent restenosis lesions in the ST group. QCA was
completed in 393 lesions with ST and in 432 lesions
from the control group. The baseline angiographic
characteristics and the post-procedural angiographic
outcomes of index lesions are displayed in Table 4.
Lesions with subsequent ST had more thrombi and a
higher rate of Thrombolysis In Myocardial Infarction
(TIMI) ﬂow grade 0/1 at the time of baseline DES
implantation. Final procedural angiographic analysis
demonstrated larger in-stent diameter stenoses and
longer stented segments in the ST group.
OCCURRENCE OF LATE/VERY LATE ST. The time
distribution from DES implantation to ST is displayed
in Figure 2. The majority of late/very late ST events
occurred after 1 year (75%) and continued to occur aslong as 7.3 years. The median time from DES implan-
tation to ST was 764 (IQR: 376 to 1,338) days. The
clinical presentation of late/very late ST was predom-
inantly MI (66.7% STEMI and 22.0% non-STEMI);
among those patients, 4.7% presented with cardio-
genic shock. At the time of ST, visual thrombus was
documented in 98.8% and TIMI ﬂow grade 0 was
observed in 74.6% of the patients. Of the lesions that
underwent repeat PCI at the time of ST presentation,
9.9% underwent pre-intervention intravascular ultra-
sound. The rates of stent malapposition (per investi-
gator determination) conﬁrmed by angiography was
5.9% (26 lesions) and by intravascular ultrasound was
4.7% (21 lesions). Of the thrombotic lesions that un-
derwentofﬂineQCA, the thrombuscharacteristicswere
total occlusion in 73%, diffuse thrombosis through-
out the stent and lesion in 14.1%, focal thrombosis in
9.2%, and stent edge thrombosis in 3.2% of the lesions.
DUAL-ANTIPLATELET THERAPY AND LATE/VERY
LATE ST. DAPT adherence rates at the time of the
event are shown in Table 5. Overall, 30.2% of patients
were receiving DAPT at the time of late/very late ST;
11% stopped the DAPT within 5 days before the
thrombosis. As anticipated, there was a stark differ-
ence between the rate of DAPT cessation at the time
of ST presentation between the patients presenting at
30 days to 1 year and beyond 1 year (49.1% vs. 78.3%,
p < 0.001, respectively). In those patients who had
events within the ﬁrst year after the DES implanta-
tion, 51.8% were receiving DAPT, and for those who
had the ST after 1 year, 23.1% were receiving DAPT at
the time of event.
LATE/VERY LATE ST TREATMENT AND OUTCOMES.
Thrombus aspiration was performed in 47% of the
patients who presented with late ST and balloon
angioplasty in 78.1%; DES reimplantation was per-
formed in 30.8% of the lesions and BMS in 20.6% of
the lesions. Admission to the intensive care unit was
required in 72.4% of the patients. The median dura-
tion in the ICU was 5 (IQR: 1 to 2) days, and total
length of stay was 3 (IQR: 2 to 5) days. The late ST
in-hospital mortality rate was 3.7%, reinfarction
(STEMI) rate was 0.8%, coronary artery bypass graft
rate was 2.9%, repeat PCI rate was 2.2%, acute renal
failure rate was 4.1%, stroke (either ischemic or
hemorrhagic) rate was 0.4%, and recurrent ST within
the same hospitalization rate was 0.6%. All-cause,
out-of-hospital mortality rate at 12 months after
ST presentation was 2.87%, and the overall major
adverse cardiac event rate was 16.4%.
UNIVARIATE AND MULTIVARIATE CORRELATES OF
LATE/VERY LATE ST. The univariable clinical and
TABLE 3 Lesion Data at Time of Drug-Eluting Stent Implantation
ST
(n ¼ 531)
Control
(n ¼ 658) p Value
Left main, % 0.4 1.1 0.31
Right coronary artery, % 35.8 36.0 0.933
Left anterior descending artery, % 41.8 36.5 0.06
Left circumﬂex, % 17.1 24.9 0.001
Saphenous vein graft, % 4.7 1.4 <0.001
Arterial graft, % 0 0.2 1
Lesion location, %
Ostial 5.5 3.8 0.17
Proximal 42.0 39.8 0.45
Bifurcation 9.1 7.2 0.23
Lesion classiﬁcation (visual), % <0.001
A 11.1 17.8
B1/B2 44.8 54.1
C 44.1 28.1
Pre-diameter stenosis visual, % 87.0  11.3 85.4  11.2 0.015
Lesion length visual, mm 20.79  13.2 17.2  10.1 <0.001
Reference vessel diameter visual, mm 3.0  0.4 3.0  0.5 0.27
Visual thrombus, % 20.8 14.1 0.003
Pre-TIMI ﬂow, % <0.001
3 66.5 80.5
2 13.0 9.2
1 4.0 2.3
0 16.4 8.0
In-stent restenosis (any stent type), % 10.4 4.7 <0.001
In-stent restenosis (drug-eluting stent), % 4.5 1.7 0.004
Chronic total occlusion, % 2.8 2.9 0.95
Moderate/severe calcium (visual), % 15.9 13.6 0.71
Stent type, %
Sirolimus-eluting stent 50.8 49.8 0.74
Paclitaxel-eluting stent 41.6 39.3 0.43
Zotarolimus-eluting stent 2.3 1.4 0.27
Everolimus-eluting stent 5.7 8.1 0.12
Other 0.2 0.6 0.39
Stent diameter, mm 2.9  0.4 3.0  0.4 0.007
Total stented length, mm 27.8  16.7 23.3  12.6 <0.001
Maximal deployment pressure, atm 14.1  3.1 14.0  3.2 0.64
No. of stents per lesion 1.3  0.6 1.2  0.5 <0.001
Stent overlap, % 37.4 23.9 <0.001
Values are mean  SD.
ST ¼ stent thrombosis; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1097angiographic correlates and the combined clinical and
angiographic correlates for late/very late ST are
shown in Table 6. Younger patients, African Ameri-
cans, patients who smoked at the time of initial DES
implantation, patients with multivessel disease,
those treated with overlapping stents, those with
longer total stented length, and patients with SVG
lesions were among the most important univariable
clinical correlates, whereas LAD location, the pres-
ence of thrombus, ﬁnal in-stent diameter stenosis,
and SVG lesion location were among the most
important angiographic univariable correlates. When
combining the clinical and angiographic correlates
into 1 model, the independent correlates for devel-
opment of late ST were younger patients, smokers at
the time of initial DES implantation, STEMI or the
presence of thrombus by QCA at the time of initial
DES implantation, the number of diseased vessels,
type C lesions, longer total stented length, and
overlapping stents.
DISCUSSION
The DESERT is the largest case-control study of late/
very late thrombosis of DES. The main ﬁndings of this
analysis were that the majority of late ST occurred
after 1 year and continued to occur >7 years after the
initial DES implantation. Approximately 30% of the
patients with late ST were receiving DAPT at the time
of the event, and although the clinical presentation of
late ST was mainly MI, the overall outcome, including
mortality rates, is lower compared with acute or
subacute ST.
Independent clinical predictors of the occurrence
of late ST were younger age, smoking at the time of
initial DES implantation, multivessel disease, type C
lesions, longer stent length, and overlapping stents.
Independent angiographic predictors as assessed by
QCA were LAD or a bypass graft, a larger residual
diameter stenosis after DES implantation, and the
presence of thrombus. The in-hospital and long-term
morbidity and mortality rates with late ST were lower
compared with historically reported rates of acute
and subacute ST.
Subacute DES thrombosis is a devastating event
associated with high mortality and morbidity rates
(6,11,15). This phenomenon is subject to ongoing in-
vestigations to better understand the pathophysiology
and to develop measures for its prevention. So far
mechanical, biological, and/or patient-related factors
have been identiﬁed as etiologies. Among the mecha-
nistic etiologies are stent strut fractures (24), lack of
full stent expansion, incomplete stent apposition to
the vessel wall related to inadequate lesionpreparation, and lack of post-dilation (25). Biological
etiologies are mainly related to delayed or incomplete
healing, incomplete re-endothelialization, inﬂamma-
tion, and late restenosis (26,27). Among the patient-
related factors associated with ST are noncompliance
with DAPT and nonresponsiveness to DAPT; specif-
ically genomic mutations and polymorphisms have
been identiﬁed as strong correlates for ST (28–32).
However, these etiologies are mainly related to acute
and subacute ST (33,34). Although several studies have
examined correlates of ST as long as 1 year from the
time of DES implantation, to date, no study has
focused exclusively on correlates of late and very late
TABLE 4 Angiographic Lesion Characteristics by Quantitative Coronary Angiography
ST, %
(n ¼ 393)
Control, %
(n ¼ 432) p Value
Thrombus, % 40.1 29.4 0.001
Tortuosity (moderate/severe), % 2.3 1.6 0.65
Calciﬁcation (moderate/severe), % 14.8 12.6 0.43
Aneurysm, % 0.3 0 0.48
Pre-TIMI ﬂow, % <0.001
3 65.4 78.2
2 13.0 6.7
1 3.3 3.7
0 18.3 11.3
Angulation >45 9.4 12.7 0.13
Reference vessel diameter, mm 2.76  0.43 2.71  0.45 0.09
Lesion length, mm 19.77  12.14 16.86  10.05 <0.001
Pre-minimal lumen diameter, mm 0.67  0.47 0.74  0.46 0.03
Pre-diameter stenosis, % 75.93  16.35 72.79  15.80 0.005
Final reference vessel diameter, mm 2.83  0.44 2.77  0.45 0.08
Final TIMI ﬂow, % 0.70
0 0.5 0.5
1 0.3 0.5
2 3.1 1.9
3 96.2 97.2
Final in-segment minimal lumen diameter, mm 2.27  0.42 2.26  0.45 0.70
Final in-stent minimal lumen diameter, mm 2.56  0.41 2.60  0.46 0.275
Final in-segment diameter stenosis, % 19.66  8.22 18.66  8.54 0.09
Final in-stent diameter stenosis, % 9.04  9.09 6.20  9.29 <0.001
Final in-segment acute gain, mm 1.60  0.53 1.52  0.56 0.03
Final in-stent acute gain, mm 1.89  0.53 1.86  0.54 0.31
Final stented segment length, mm 28.44  15.64 22.97  12.47 <0.001
Dissection, % 0.3 0.2 1.00
Values are mean  SD. Only those lesions where ST subsequently occurred were included for the case patients.
Abbreviations as in Table 3.
FIGURE 2 Time From DES Implantation to ST Event
A majority of the late/very late ST presentations were beyond 1 year from the
DES implantation, with 35% presenting >3 years after the DES implantation.
Abbreviations as in Figure 1.
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1098DES thrombosis mainly due to the low frequency of
late ST events beyond 1 year (<1%).
The low ST rate per study limits the simultaneous
assessment of multiple risk factors. For example, a
study of 5,000 patients would have onlyw100 late ST
events, with the ability to reliably assess only 5 to 10
correlates. By using a case-control design with limited
matching (only for site and time to thrombosis),
our study allowed the simultaneous assessment of a
broad range of associations between clinical and
angiographic predictors and late ST.
During the conduction of the present study, 492
patients with deﬁnite late/very late ST were identi-
ﬁed. Interestingly, the majority of the ST events in
this study (w75%) occurred after 1 year from the DES
implantation and continued to occur as long as
7.3 years. The Bern Rotterdam group reported a
continued hazard ratio of the DES thrombosis up to
5 years with a rate as high as 0.6% per year (35).
This continued hazard ratio of late ST was not previ-
ously described with BMS, and although the rate of
late ST has decreased with second-generation DES,
there are no data to ensure patients that they are no
longer at risk of the development of ST at any time
point after DES implantation. Therefore, identifying
these at-risk groups is critical in potentially reducing
the incidence of the late/very late DES thrombosis
phenomenon.
CLINICAL CORRELATES. Among the clinical corre-
lates of late/very late ST detected in the DESERT were
a number of factors associated with more aggres-
sive and extensive coronary disease. These factors,
although not overwhelmingly strong, included
younger age, active smoking, multivessel disease,
overlapping stents, and previous bypass surgery. Of
note, this analysis did not independently identify
ACS presentation (including STEMI) as a correlate of
late/very late ST. This ﬁnding is intriguing and may
reﬂect a fundamentally different pathogenesis for the
majority of late/very late events compared with sub-
acute ST (for which the presence of ACS is one of the
most predictive risk factors). Active smoking, which
is usually common in younger populations, was
detected as a strong correlate of ST, which can be
explained by the increase in platelet reactivity with
tobacco use. Despite the previously published
“smoking paradox” with clopidogrel, it is important
to emphasize that active smoking was associated with
an increase in ST in our study, which is in accordance
with other trials, such as the PLATO (PLATelet
inhibition and patient Outcomes) study (36,37).
Interestingly, the African-American study group
was found to be at a higher risk of the development of
TABLE 5 Antiplatelet Therapy Adherence
ST
(n ¼ 492)
DES
Implant
Discharge
Receiving
at ST
Not
Receiving
at ST
If Not, Stopped
Within
5 Days of ST
Unknown
at ST
Aspirin, % 99.2 74.8 24.5 18.1 3.5
Clopidogrel, % 98.6 32.4 65.5 15.3 4.3
Ticlopidine, % 1.2 0.4 1.2 0 1.2
Prasugrel, % 0.4 0.4 0 — —
Dual-antiplatelet therapy, % 99.2 30.2 71.1 11.0 2.0
ST #1 Year
(n ¼ 120)
ST >1 Year
(n ¼ 371)
p ValueOn Off On Off
Aspirin, % 77.4 20.9 74.0 25.7 0.356
Clopidogrel, % 54.8 43.5 25.1 72.6 <0.001
Ticlopidine, % 0.8 0 0.3 1.6 0.344
Prasugrel, % 0.8 0 0.3 0 —
Dual-antiplatelet therapy, % 51.8 49.1 23.1 78.3 <0.001
DES ¼ drug-eluting stent(s); ST ¼ stent thrombosis.
TABLE 6 Clinical and Angiographic Correlates of Late/Very Late Stent Thrombosis
Variable
Clinical, OR
(95% CI) Angiographic
Combined, OR
(95% CI)
Age 0.964 (0.95–0.98) * 0.793 (0.96–0.99)
Hypertension 0.757 (0.51–1.12) * 0.863 (0.56–1.34)
Body mass index 0.979 (0.95–1.01) * 0.981 (0.95–1.01)
ACS/NSTEMI 1.084 (0.70–1.67) * 0.831 (0.54–1.28)
Left anterior descending lesion 1.107 (0.77–1.59) 1.671 (1.21–2.32) 1.302 (0.87–1.96)
Current smoker 1.890 (1.26–2.85) * 1.633 (1.05–2.53)
STEMI or thrombus (QCA) 1.059 (0.62–1.80) 1.486 (1.03, 2.14) 1.062 (0.66–1.71)
African American 2.346 (1.21–4.54) * 1.612 (0.65–3.99)
Diabetes 0.915 (0.60–1.40) * 1.021 (0.65–1.60)
Renal insufﬁciency 1.019 (0.50–2.09) * *
No. of diseased vessels 1.313 (1.05–1.65) * 1.712 (1.32–2.22)
Type C lesion (QCA) * 0.939 (0.54–1.63) 2.188 (1.38–3.47)
Final reference vessel diameter, mm * 1.190 (0.77–1.85) 1.436 (0.84–2.44)
Acute gain, mm * 0.982 (0.64–1.51) 1.013 (0.64–1.61)
Final in-stent diameter stenosis * 1.021 (1.00–1.04) 1.014 (0.99–1.04)
Total stented length 1.015 (1.00–1.03) 1.022 (1.00–1.05) 0.977 (0.97–0.99)
Bypass graft lesion 3.306 (1.18–9.27) 3.900 (1.55–9.84) 1.997 (0.60–6.70)
Lesion length (QCA) * 0.999 (0.97–1.03) *
Overlapping stents 1.757 (1.18–2.61) * 2.220 (1.34–3.69)
Each of the 3 models (clinical, angiographic, and combined) were run independently. *Variable not included in
this particular model. Signiﬁcant correlates are indicated in bold.
ACS/NSTEMI ¼ acute coronary syndrome/non–ST-segment elevation myocardial infarction; CI ¼ conﬁdence
interval; OR ¼ odds ratio; QCA ¼ quantitative coronary angiography; STEMI ¼ ST-segment elevation myocardial
infarction.
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1099late ST, which could be explained by the higher
complexity of the disease in this group and/or the
potential for higher platelet reactivity on clopidogrel,
a phenomenon previously reported in this group
(38,39). It is also know that this population has higher
rate of CYP2C19*2 and CYP2C9*3 polymorphism (40).
Although our analysis did not detect the presence of
ACS including STEMI as a clinical correlate for ST, the
presence of thrombus at the time of the DES implan-
tation was a predictor of late ST. This may differen-
tiate ACS with and without the presence of a
thrombus and corroborate previous reports of the
impact of the presence of thrombus and thrombus
size on late outcome (41,42).
ANGIOGRAPHIC CORRELATES. Among the cohort of
patients with core laboratory–assessed angiographic
data, greater residual in-stent diameter stenosis post-
implantation, the presence of thrombus, and LAD or
vein graft lesions were the main angiographic corre-
lates of late/very late ST. Interestingly, bifurcation
and in-stent restenosis lesions, both of which have
previously been reported as correlates of DES
thrombosis, were not detected as independent cor-
relates of late/very late ST in the DESERT cohort. This
may be explained by the fact that the previous studies
focused on correlates of ST as long as 1 year (including
acute and subacute ST), whereas in the DESERT reg-
istry, nearly 75% of the events occurred beyond 1 year
after DES implantation. It is possible that the corre-
lates for DES thrombosis beyond 1 year are different
from those correlates for early time points of ST. Of
note, combining both clinical and angiographic cor-
relates into a combined multivariable model identi-
ﬁed younger age, current smoker, multivessel
disease, type C lesions, longer total stent length, and
overlapping stents as the strongest correlates in this
combined model.
ANTIPLATELET THERAPY. The most powerful pre-
dictor of DES thrombosis is early cessation of DAPT,
especially within the ﬁrst 30 days of stent implanta-
tion (31,32,39). By design, the DESERT focused
exclusively on patients who had the event beyond
30 days, so discontinuation of DAPT at that early time
was not applicable for this registry. In the DESERT, in
patients who had ST within the ﬁrst year, half were
receiving DAPT at the time of the event, and after the
ﬁrst year, nearly one-fourth of the patients who had
very late ST were receiving DAPT. These ﬁndings
suggest that taking DAPT is not a magic bullet for
preventing late ST, and other non–antiplatelet-
related mechanisms may contribute to the late ST
phenomenon. Among these potential mechanisms are
late restenosis with progression or narrowing of thestent lumen and neoatherosclerosis as a result of local
inﬂammation of the polymer that may result in
rupture of a new form of atherosclerotic plaque
(43,44). Neither mechanism is related to incomplete
healing or is known to be protected by DAPT.
Although the guidelines recommend at least
12 months of DAPT (45,46), the optimal duration of
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1100DAPT post-DES implantation remains controversial:
some suggest 3 to 6 months, whereas others
suggest $24 to 36 months for this high-risk popula-
tion. The DESERT does not support the idea that a
longer duration of DAPT beyond 1 year will further
reduce very late ST. Perhaps the focus should be
broadened to include not only DAPT duration but
also recognize the other associated correlates as
detected in the DESERT.
CLINICAL PRESENTATION AND OUTCOME. Although
the main presentation of the patients with late/very
late DES thrombosis was MI, and nearly 75% of these
patients presented with TIMI ﬂow grade 0 on angi-
ography, the clinical outcome of late/very late ST was
favorable in terms of in-hospital and 1-year mortality
compared with historical series of patients with acute
and subacute DES thrombosis.
van Werkhum et al. (22) reported on a cohort of 437
ST patients initially treated with BMS and DES and
observed an in-hospital mortality rate of 6% and a
1-year mortality rate of 10.7%, which is 3 times higher
than what we observed. This substantial difference in
mortality can be explained by the time interval be-
tween the ﬁrst DES implantation to the ST event that
allows the patient to recover from the ﬁrst event.
Only 26% of ST patients presented with late ST in the
Dutch registry, whereas only patients with late ST
were included in our registry. Another explanation
could be related to the mechanism for late/very late
ST. In the case of late restenosis or neoatherosclerosis
within the stent, the event is not as abrupt as with
subacute DES thrombosis, and the patient may
experience preconditioning ischemia, or collaterals
may even develop that mitigate the adverse clinical
outcome of the ST event.
Early-generation DES, compared with BMS, were
associated with an increased risk of very late ST;
however, mortality rates did not differ. Our observa-
tion of low mortality after late/very late ST explains at
least in part why differences in ST did not translate
into an increased mortality with DES. Conversely,
newer generation DES have been associated with a
decrease in both early and late/very late ST (47,48)
compared with BMS. Whether this will translate into
a mortality beneﬁt in favor of newer generation DES
remains to be seen.
Despite the modest presentation of late/very late
DES thrombosis compared with acute and subacute
ST, it is not a benign phenomenon and continues to
be unpredictable in its occurrence for patients un-
dergoing DES implantation (49). Once the mecha-
nisms of the phenomenon are better understood, this
phenomenon may be prevented or eliminated. Itwould be interesting to follow newer generation
DES, particularly with biodegradable polymers and
scaffolds, to determine whether changes in the
device can minimize its incidence. Meanwhile, a
focus on modiﬁable risk factors, such as smoking,
should be emphasized for patients undergoing stent
implantation.
STUDY LIMITATIONS. The DESERT has several lim-
itations. First, as a case-control study, we were
unable to provide direct insight into the incidence
of late/very late ST in the study population. In
addition, in the DESERT, 90% of the patients in
both groups had ﬁrst-generation DES and different
correlates may apply for second-generation DES.
Finally, because we wanted to use a highly speciﬁc
deﬁnition of ST, virtually all of the ST cases in our
series are patients who survived to coronary angi-
ography. As a result, we may have underestimated
the prognostic impact of late/very late DES throm-
bosis (by excluding patients whose initial presen-
tation was sudden cardiac death. Nevertheless, the
DESERT registry is the largest report of patients
who presented with late/very late ST, and given the
millions of patients who are living with DES, the
results of the study can be used to alert physicians
and patients to the potential late risk of this
phenomenon.
CONCLUSIONS
Patients with ﬁrst-generation DES continue to be at
risk of late ST beyond 7 years. Younger patients,
smokers at the time of initial DES implantation,
patients with multivessel disease, bypass grafts, or
thrombus are at higher risk of the development of late
ST and should therefore be considered for alternative
treatments. The lower mortality rates seen with late
ST compared with historically reported acute and
subacute ST suggest a different pathological mecha-
nism for this phenomenon (late restenosis and/or
neoatherosclerosis). The role of antiplatelet therapy
to prevent late ST is not proven to be beneﬁcial, and
further improvement in the technology of DES is
required to minimize the phenomenon of late ST.
Meanwhile, we hope that knowing the correlates of
late DES thrombosis as they are identiﬁed in the
DESERT may be useful to minimize this troubling
phenomenon.
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